GlassScriptPhysician profile
Karen H Krusinga
NPI 1629260252
$5,087.54
in general payments reported to CMS, 2019-2025
14 companies · $2,858 in 2025
The $2,858 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $441 · 2024: $1,789 · 2025: $2,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,865 · Education: $205 · Travel and Lodging: $17.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,865.35 |
| Education | $204.63 |
| Travel and Lodging | $17.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $796.47 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $794.98 | 2023-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $751.26 | 2023-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $484.06 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $477.20 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $423.95 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $399.86 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $260.96 | 2024-2025 | Austedo Xr, Uzedy |
| Abbvie INC. | $243.20 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $195.13 | 2023-2024 | Invega Sustenna, Spravato |
| Supernus Pharmaceuticals, INC. | $92.15 | 2025 | Qelbree |
| Lundbeck LLC | $90.81 | 2024-2025 | Rexulti |
| Indivior INC. | $41.79 | 2023-2024 | Perseris, Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $35.72 | 2023-2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Krusinga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.